Controlled trial of N-acetylcysteine for patients with probable Alzheimer’s disease
Top Cited Papers
- 23 October 2001
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Neurology
- Vol. 57 (8) , 1515-1517
- https://doi.org/10.1212/wnl.57.8.1515
Abstract
The antioxidant N-acetylcysteine (NAC) or placebo was administered in a double-blind fashion to patients who met National Institute of Neurological and Communicative Disorders and Stroke–Alzheimer’s Disease and Related Disorders Association criteria for probable AD. Testing for efficacy occurred after 3 and 6 months of treatment. Comparison of interval change favored NAC treatment on nearly every outcome measure, although significant differences were obtained only for a subset of cognitive tasks.Keywords
This publication has 10 references indexed in Scilit:
- The Role of Oxidative Stress in Alzheimer DiseaseArchives of Neurology, 1999
- An Assessment of Oxidative Damage to Proteins, Lipids, and DNA in Brain from Patients with Alzheimer's DiseaseJournal of Neurochemistry, 1997
- A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's DiseaseNew England Journal of Medicine, 1997
- Oxidative damage to mitochondrial DNA is increased in Alzheimer's diseaseAnnals of Neurology, 1994
- N-acetyl-l-cysteineJournal of Cellular Biochemistry, 1993
- Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease.Proceedings of the National Academy of Sciences, 1991
- Autopsy Samples of Alzheimer's Cortex Show Increased Peroxidation In VitroJournal of Neurochemistry, 1990
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984
- Assessing Self‐maintenance: Activities of Daily Living, Mobility, and Instrumental Activities of Daily LivingJournal of the American Geriatrics Society, 1983
- Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily LivingThe Gerontologist, 1969